CAPR Stock On Track To Clock Weekly Gains Ahead Of Critical FDA Panel — Retail Deems It A ‘Binary Event’

CAPR stock is on track for weekly gains ahead of an FDA advisory committee meeting.

The FDA advisory committee will review Capricor's application for Deramiocel on July 29.

Retail investors deem the FDA decision a 'binary event' for the stock.

The outcome of the panel review could significantly impact Capricor's stock price.